Modular Molecular Affinity Clamps for Short Peptide Motifs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current affinity reagents, such as antibodies and nucleic acid aptamers, face challenges in generating high-performance binders for short peptide motifs, particularly those involved in signaling and cancer biology, due to difficulties in achieving high affinity and specificity, scalability, and reproducibility.
Innovation Solution
Development of modular molecular affinity clamps with a clamp-like architecture, comprising a specificity shell and an enhancer shell, engineered to bind short peptide motifs with enhanced affinity and specificity, utilizing natural binding domains and engineered antibody mimics to create high-affinity, high-specificity reagents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used as affinity reagents for short peptide motifs, then high affinity and specificity can be achieved, but the production is difficult, time-consuming, and expensive
Solution Approach 1:
The invention divides the affinity reagent into two separate domains: a specificity-determining domain that binds the peptide motif and an affinity-enhancing domain that increases binding strength. This segmentation allows each domain to be optimized independently, with the specificity domain derived from natural peptide-binding domains and the affinity domain engineered to provide enhanced binding, thereby achieving high affinity and specificity while simplifying production
Solution Approach 2:
The invention creates a composite affinity reagent by fusing two different protein domains together. The first domain provides motif-specific recognition while the second domain contributes affinity enhancement. This composite structure combines the advantages of both domains, achieving antibody-like performance with the production benefits of recombinant protein technology
2Ease of manufacture
If polyclonal antibodies are used for affinity reagents, then upfront costs are low, but reproducibility and scalability are poor
Solution Approach 1:
The invention uses recombinant DNA technology to create identical copies of the affinity reagent gene. This allows the exact same protein sequence to be produced repeatedly in bacterial or mammalian expression systems, ensuring complete reproducibility between batches and laboratories while maintaining low production costs through scalable recombinant expression
3Reliability
If affinity reagents are generated for short peptide motifs, then high affinity can be achieved, but scalability and archiving are limited
Solution Approach 1:
The invention changes the fundamental parameters of affinity reagent production by using recombinant DNA sequences instead of traditional antibody generation methods. This allows the affinity reagent to be produced in large quantities through bacterial or mammalian expression systems, enabling scalability and long-term archiving while maintaining high affinity through optimized domain design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modular molecular affinity clamps achieve >2,000-fold enhancement in affinity and specificity, enabling low nM dissociation constants and scalable, economical production, suitable for immunochemical applications and label-free biosensing.
Implementation Method 1
affinity reagents embodying the principles of the invention possess affinity and specificity for short peptide target motifs of interest
Data Source
AI summary
The invention provides a molecular affinity clamp. The architecture of the affinity clamp is modular with two biorecognition modules, each capable of binding a target motif. The first biorecognition module has a recognition domain that possesses inherent or natural specificity for the target motif. The second biorecognition module also has a recognition domain that binds the motif. The two biorecognition modules are tethered together either directly, e.g., via a peptide bond between the two modules, or indirectly, e.g., via a linker moiety or linker.